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Abstract: DBS for Parkinson’s disease (PD) may be underutilized because of limited access to care (most
DBS surgeries are performed at specialized centers) or over-referral of poor candidates, leading to
inequitable utilization of limited evaluative resources. There is a pressing need for a widely employable
screening algorithm to aid in the evaluation of PD candidates for DBS. The aim of this study was to compare
the validity and efﬁcacy of two published screening algorithms, the Florida Surgical Questionnaire for PD and
Stimulus, to predict candidacy for DBS. We reviewed the clinical data at our DBS center for 147 consecutive
PD DBS referrals between 1 September 2007 and 31 December 2011. Florida Surgical Questionnaire and
Stimulus scores were applied retrospectively through a chart review of the movement disorder neurologist’s
initial clinical evaluation. The validity and accuracy of these two algorithms in predicting candidacy for DBS
was compared to the decision to offer DBS surgery by our multidisciplinary DBS team. Of the 130 consecutive
PD referrals who presented for initial evaluation, 50 were offered DBS after a standardized multidisciplinary
evaluation. The Stimulus scale was a superior screening tool for predicting PD DBS candidacy in these
referrals (area under the receiver operating curve [AUROC] = 0.8088), compared to the Florida Surgical
Questionnaire for PD (AUROC = 0.6285). In this single-center study, Stimulus was a more appropriate
screening measure than the Florida Surgical Questionnaire for PD to assess DBS candidacy for PD.
DBS is a well-established surgical therapy for Parkinson’s disease
(PD) patients with medication-refractory tremor or bothersome
motor fluctuations, despite an optimized medication regimen.1
DBS has traditionally been considered only for advanced PD
patients,2 but the results of a recent European trial suggest that
PD patients who are earlier in the course of their disease (i.e.,
within 3 years of developing motor fluctuations) may also have
significant benefit from DBS.3
Among Medicare beneficiaries in the United States, the pri-
mary responsibility for the longitudinal care of patients with PD
is shared relatively evenly between neurologists and primary
care physicians.4 Greater than 90% of DBS surgery, however, is
performed at urban tertiary care facilities.5 Primary care physi-
cians may not be aware of when a patient would qualify for
DBS, raising the possibility of heterogeneity in access to DBS.
Successful DBS outcomes depend heavily on appropriate patient
selection, with poorly selected candidates accounting for
approximately one third of DBS treatment failures.6 Thus, DBS
may be underutilized because of limited access to care or over-
referral of poor candidates, leading to inequitable utilization of
limited evaluative resources.
Two published algorithms are available to aid non–move-
ment disorder clinicians in deciding whether or not to refer
PD patients for DBS evaluation: the Florida Surgical Question-
naire for Parkinson Disease (FLASQ-PD)7 and the Stimulus
tool.8 We explored the validity and efficacy of these two
screening algorithms in a cohort of PD patients evaluated for
DBS candidacy at the University of Michigan (UM) Surgical
Therapies Improving Movement (STIM) Program, using an
affirmative decision to offer DBS surgery after the multidisci-
plinary STIM team evaluation as the comparative reference
standard.
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Patients and Methods
Subjects
We conducted a retrospective cohort study of 147 consecutive
idiopathic PD (iPD) patients newly referred for consideration of
DBS at the UM STIM program between 1 September 2007
and 31 December 2011 (Fig. 1). All referrals for DBS were
logged at the time of referral, and all patients were subsequently
scheduled for an initial clinic evaluation with a movement
disorder neurologist (K.L.C.). At their initial clinic visit,
patients were considered to be good candidates for further DBS
evaluation if they had motor fluctuations not optimally managed
by medications or a severe rest tremor despite high doses of
dopaminergic treatment. Medication strategies that had to be
tried for wearing-off symptoms included adjusting levodopa fre-
quency, adding or increasing the dosage of dopamine agonists,
and addition of a catechol-O-methyl transferase (COMT) or
monoamine oxidase (MAO)-B inhibitor. For dyskinesias, medi-
cation strategies that had to be tried included addition of aman-
tadine, decreasing dosage of L-dopa, and discontinuing COMT
inhibitors or MAO-B inhibitors. Tremor was labeled refractory
to medications if it still interfered with quality of life despite a
daily L-dopa dose of >1,000 mg and a trial of trihexyphenidyl.
If patients had dementia, clear lack of motor response to L-dopa
(other than medication-refractory tremor), an unstable psychiat-
ric condition, or a desire for improvement in symptoms not
expected to improve with DBS (such as gait instability requiring
a walker even in the best medication on state), no further pre-
surgical evaluation was performed. Those individuals who
passed the initial screening clinic evaluation then completed a
standardized multidisciplinary workup, including 3T MRI of
the brain, a standardized OFF-ON evaluation using the Interna-
tional Parkinson and Movement Disorder Society/UPDRS
(MDS-UPDRS) motor exam to assess for response to dopami-
nergic therapy,9 a comprehensive neuropsychological evaluation
(see Appendix 1 in the Supporting Information), neurosurgical
consultation, a formal speech evaluation, and social work con-
sultation. After all these evaluations were completed, prospec-
tive candidates were discussed at a multidisciplinary STIM team
meeting, where a consensus formal decision was made about
whether or not to offer the patient STN-DBS surgery.
Figure 1 Flowchart of subjects.
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In general, the STIM team used the following criteria for
deciding whether or not to offer DBS surgery: (1) motor fluc-
tuations and/or severe dyskinesias that interfere with quality of
life despite optimal medical management or medically refractory
parkinsonian tremor; (2) a dopaminergic medication response of
at least 30% in the ON-medication state, compared to the
OFF-medication state (patients with medication-refractory tre-
mor did not need to meet this criteria), as measured by the
MDS-UPDRS, part III; (3) no evidence for dementia based on
neuropsychological testing; (4) the absence of refractory or
severe psychiatric symptoms based on screening questionnaires
(see Appendix 1 in the Supporting Information); and (5) no
other medical contraindications for surgery.
The STIM team criteria listed above are intentionally broad,
given that many clinical scenarios demand considerations that
do not lend themselves to inflexible cutoffs. As an example, the
degree of dyskinesia or motor fluctuations warranting surgery
depends on individual factors, including occupational status and
patient goals. Furthermore, results on cognitive tests might be
interpreted differently depending on the patient’s educational
status. Thus, we did not utilize strict cut-off values for any
motor, cognitive, or psychiatric rating scales, other than the
30% OFF-ON improvement in the MDS-UPDRS. The sever-
ity of any motor, cognitive, or psychiatric deficits were given
differential consideration in the context of the patient’s back-
ground and goals.
Screening Algorithms
For each patient, FLASQ-PD and Stimulus scores were calcu-
lated through a chart review of the movement disorder neurolo-
gist’s initial clinical evaluation. FLASQ-PD is a brief, five-part
evaluation7 that assesses (1) criteria for the diagnosis of PD, (2)
potential contraindications to DBS surgery, (3) general patient
characteristics, such as age, duration of symptoms, presence of
and dyskinesias/fluctuations, (4) favorable or unfavorable charac-
teristics with regard to DBS surgery, such as L-dopa response,
and (5) a history of previous medication trials. Individual scores
from parts 3 to 5 are summed, yielding a final FLASQ-PD score
ranging from 0 (worst possible) to 34 (best possible). A cut-off
score of 25 or greater has been suggested to identify optimal
candidates and scores of 15 or less indicate poor candidates.7
Stimulus is a two-part online decision tool developed using
the RAND/UCLA Appropriateness method8 and can be found
online (http://test.stimulus-dbs.org). Potential DBS candidates
must first meet five absolute criteria in part 1: (1) a diagnosis of
iPD; (2) troublesome motor symptoms despite optimal pharma-
cological treatment; (3) clear motor improvement with L-dopa;
(4) the absence of significant medical conditions preventing sur-
gery; and (5) the absence of significant medically resistant men-
tal disease, such as depression or dementia. If these criteria are
not met, the patient “does not meet the requirements for con-
sideration of DBS” and no score is given. If a prospective DBS
candidate meets all five of the absolute criteria in Stimulus part
1, they are scored on part 2 for seven key variables: age; disease
duration; severity of symptoms during the OFF medication
state; severity of dyskinesias; L-dopa-unresponsive axial symp-
toms; refractory tremor; and intellectual impairment. Once
these are entered, the Stimulus program displays a score from 1
to 9. Scores of 7 or greater are considered “appropriate.” Scores
of 4 to 6 are “uncertain” and scores of 3 or less are “inappro-
priate.”
For our study, all patients presenting for initial clinic evalua-
tion were given FLASQ-PD and Stimulus part 2 scores, even if
they would have been excluded based on FLASQ-PD section 2
(potential contraindications) or Stimulus part 1. This was done
to enhance the generalizability of both screening algorithms
given that the interpretation of these sections may vary depend-
ing on one’s expertise with PD DBS patient selection. As an
example, “optimal pharmacological management” might be
different for a primary care physician, compared to a movement
disorders specialist. Moreover, if Stimulus part 1 criteria were
strictly followed, some PD patients whose tremor did not
respond to high doses of L-dopa would not be considered DBS
candidates.
Human Subjects and Standard Protocol
Approval
The study was approved by the institutional review board of
UM.
Statistical Analysis
The decision by the STIM team to offer DBS surgery served as
the comparative reference standard for FLASQ-PD and Stimu-
lus scores. Receiver operating curves (ROCs) were calculated
for each scale in order to determine the area under the curve
(AUC). The AUC for each of the two scales was estimated
using Mann-Whitney’s U test. ROC contrast estimation
between the two scales and between the FLASQ-PD scale with
chance alone were calculated using Wald’s chi-square testing.
Sensitivity, specificity, positive predictive value (PPV), and neg-
ative predictive value (NPV) were calculated for FLASQ-PD
scores using two different cutoffs: ≥25 or ≥15. A similar analysis
was performed for the Stimulus scale using cutoffs of ≥7 or ≥3.
The interscale agreement between the FLASQ-PD and Stimulus
scales was calculated using Cohen’s kappa.
In order to explore the effects of variable interpretation and
utilization of each of the two scales, we also conducted a sensi-
tivity analysis with two subsets of the overall cohort, excluding
subjects who had potential contraindications as assessed in part 2
of the FLASQ-PD scale or who did not meet all five absolute
criteria in Stimulus part 1 criteria. All statistical analyses were
performed using SAS 9.3 (SAS Institute Inc., Cary, NC).
Results
Of the 147 PD patients who were newly referred for consider-
ation of DBS by the STIM team between 1 September 2007 and
31 December 2011, 50 were approved and 49 underwent DBS
for PD (Fig. 1). The cohort who presented for initial clinical
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evaluation (n = 130) included 94 men and 36 women with a
mean age of 65.2  9.3 years, mean duration of motor symptoms
of 10.6  5.9 years, and mean time since PD diagnosis of
9.2  5.6 years. Sixty-five (50%) were referred by movement
disorder neurologists, 46 (35%) by general neurologists, and
19 (15%) by non-neurologists. Mean FLASQ-PD score for the
cohort was 22.51  4.41. Mean Stimulus score was 6.54  2.41
for the entire cohort. Of the 130 who presented for initial
evaluation, only 82 were placed on the DBS evaluation pathway
(Fig. 1). The most common reason for not being placed on the
DBS pathway was that medications were not optimized (21
patients), though many did not even have motor fluctuations or
severe tremor (12 patients). Of the 68 patients who completed
the multidisciplinary DBS evaluation, 18 were not approved by
the STIM team. Fourteen of these were not offered DBS because
of dementia, uncontrolled depression, or <30% improvement
with OFF-ON testing. Two patients were not offered DBS for
medical reasons: 1 because of severe obesity and an implanted
pacemaker and 1 because of the development of daily syncopal
episodes resulting in multiple facial and vertebral fractures. The
remaining 2 patients decided to retry medication adjustments that
were previously documented as being of no benefit and decided
that fluctuations or dyskinesias improved to the point where it
did not interfere with quality of life.
The AUC for each scale’s ROC were estimated in order to
determine the comparative utility of each of the scales as
screening tools (Table 1; Fig. 2). The Stimulus scale showed an
AUC of 0.8088 (95% confidence interval [CI]: 0.7377, 0.8798),
which was 0.1803 (95% CI: 0.0745, 0.2860) higher than the
AUC for the FLASQ-PD scale (chi-square = 11.16;
P = 0.0008). The AUC for the FLASQ-PD scale proved
superior to chance alone by 0.1285 (95% CI: 0.0276, 0.2294;
chi-square, 6.23; P = 0.0125).
Data on the sensitivity, specificity, PPV, and NPV for each
of the two scales are presented in Table 2. The greatest degree
of sensitivity was achieved by a Stimulus cut-off score of ≥3
(sensitivity = 100%; specificity = 12.5%), and the greatest
degree of specificity was demonstrated by the FLASQ-PD scale
using a cut-off score of ≥25 (sensitivity = 50.0%; specific-
ity = 68.8%). Using a cut-off score of ≥7, the Stimulus scale
showed the highest PPV (59.7%) and highest NPV (92.5%).
Interscale agreement was poor between the lower (FLASQ-PD
≥15 and Stimulus ≥3; Cohen’s kappa: 0.046; 95% CI:
0.079, 0.012) and higher cut-off scores (FLASQ-PD ≥25
and Stimulus ≥7; Cohen’s kappa: 0.218; 95% CI: 0.067, 0.369)
for both scales.
Sensitivity Analysis
Of the 130 subjects who presented for the initial clinic evalua-
tion, 16 reported at least one potential contraindication on the
FLASQ-PD scale. After excluding these subjects from analysis,
AUCs (n = 114) for FLASQ-PD (AUC = 0.6357; 95% CI:
0.5199, 0.7515) and Stimulus (AUC = 0.7831; 95% CI: 0.7012,
0.8651) remained fairly similar to those of the overall cohort. If
those subjects who did not meet all five absolute criteria on
Stimulus part 1 were excluded, the AUCs (n = 81) for
FLASQ-PD (AUC = 0.5442; 95% CI: 0.4151, 0.6733) and
Stimulus (AUC = 0.7203; 95% CI: 0.6059, 0.8347) were
slightly lower than the values seen for the overall cohort.
Discussion
The Stimulus and FLASQ-PD screening batteries were devel-
oped to aid clinicians in assessing DBS candidacy in PD.
TABLE 1 ROCs and contrast estimation for FLASQ-PD and stimulus
Estimate Standard
Error
Lower
95% CI
Upper
95% CI
FLASQ-PD 0.6285 0.0515 0.5276 0.7294
Stimulus 0.8088 0.0363 0.7377 0.8798
D between stimulus
and FLASQ-PD curves
0.1803 0.0540 0.0745 0.2860
D between FLASQ
curve and chance
0.1285 0.0515 0.0276 0.2294
TABLE 2 Measures of validity and efﬁcacy for FLASQ-PD and
stimulus
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV (%)
FLASQ-PD
score of ≥15
96.0 2.5 38.1 50.0
FLASQ-PD
score of ≥25
50.0 68.8 50.0 68.8
Stimulus
score of ≥3
100 12.5 41.6 10/0 = inﬁnity
Stimulus
score of ≥7
92.0 61.3 59.7 92.5
Figure 2 ROC curves for FLASQ-PD and stimulus.
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Though intended for non–movement disorder specialists, both
scales contain elements that may be challenging for those
without movement disorders expertise to answer, limiting their
sensitivity. The FLASQ-PD has a potential contraindications
section (part 2), where if the answer is “yes” to any one of
these questions, the patient may not be a good candidate for
DBS. However, many of these items may not be routinely
assessed by non–movement disorder clinicians. For the Stimulus
tool, if the part 1 absolute criteria are not met, then the patient
should not be considered for DBS. One criterion is “still has
motor improvement with levodopa.” If strictly followed, some
tremor-predominant PD patients would not be referred for
DBS. In order to explicitly examine the utility of these scales as
screening instruments for non–movement disorder providers,
we decided to administer the scales to our entire cohort, even if
they would have been excluded based on FLASQ-PD part 2 or
Stimulus part 1. In this particular cohort of patients, when com-
pared to the decision of a single-center multidisciplinary DBS
team, the Stimulus scale at a cut-off score of ≥7 is a better
screening test than FLASQ-PD, with a larger AUC (0.8088) as
well as PPV (59.7%) and NPV (92.5%). This finding is not
entirely surprising given that the Stimulus part 1 criteria closely
resemble the criteria that our STIM team uses to decide DBS
candidacy. However, a sensitivity analysis excluding those sub-
jects that did not pass Stimulus part 1 and excluding those with
potential contraindications on the FLASQ-PD resulted in AUCs
that were similar or worse.
The Stimulus scale also has a few other features that may
make it more practical for clinical use by non–movement disor-
der clinicians. Most important, it focuses only on seven key
variables, so is less complex and takes less time to complete,
compared to FLASQ-PD. It is also available online and has a
color-coded visual analog scale to aid interpretation of results.
FLASQ-PD has more questions and is of longer duration. It
also includes features not likely to be evaluated by non–move-
ment disorder specialists, including primitive reflexes and ideo-
motor apraxia.
The validity and efficacy of the FLASQ-PD in determining
appropriate DBS candidates has not been reported on previ-
ously. We found a high sensitivity (96.0%) using a FLASQ-PD
score of greater than 15 as a cutoff for referral, meaning that it
would be unlikely to exclude appropriate referrals. However,
the specificity (2.5%) at that cutoff suggests that many inappro-
priate candidates would also be referred. Based on their initial
report presenting the development of the FLASQ-PD scale,
Okun et al. suggested that scores ≥25 reflected the best DBS
candidates.7 At this value in our cohort, specificity was adequate
(68.8%), but sensitivity was low (50%), suggesting that a num-
ber of appropriate candidates would not be referred.
There are several limitations to our study. Patients who were
thought to be appropriate DBS candidates at the initial screen-
ing clinic evaluation, but discontinued the multidisciplinary
pathway evaluation, would not have been discussed by the
STIM team. There were 14 such candidates, and it remains
unknown whether the STIM team would have offered them
DBS. Yet, for the purpose of this study, all of these patients
were considered “not-offered” candidates. It should be noted
that not all 130 patients underwent MDS-UPDRS I, II, and III
examinations at the time of their initial clinic assessment. Subse-
quently, we cannot draw more-detailed inferences about spe-
cific patterns of motor and nonmotor impairments that might
alter the likelihood of STIM team approval. Figure 1, however,
does provide the reasons given for those candidates who were
ultimately not offered surgery. Of the 18 subjects who com-
pleted the evaluative pathway, but were not offered DBS, 9
were not offered surgery because of severity of cognitive or
psychiatric problems, highlighting the importance of neuropsy-
chological testing in our center’s final decisions. Ascertaining
positive and negative predictive values depend on an approxi-
mation of prevalence. We have no data on those individuals
who were referred, but did not present, for initial clinical evalu-
ation or for whom data are missing. Our study explores the
validity (i.e., sensitivity and specificity) as well efficacy (NPV
and PPV) of FLASQ-PD and Stimulus, but its design does not
allow for an exploration of the reliability of these two scales
(i.e., their ability to produce consistent results in repeated
applications). Prospective studies in primary care– and commu-
nity-based referral settings will be useful to help answer these
questions.
These decision tools are designed to be applied prospectively
by a non–movement disorder specialist. In our study, FLASQ-
PD and Stimulus were completed retrospectively with the data
extracted from a movement disorder specialist’s clinical note by
an investigator not blinded to the outcome. It is impossible to
know whether the referring physicians would have prospec-
tively completed the screening tools in a similar manner. How-
ever, the sensitivity (100%) and specificity (12.5%) of Stimulus
in our study using a cutoff of 3 or greater was almost identical
to the sensitivity (99%) and specificity (12%) found in a Euro-
pean study, where Stimulus was applied in a prospective fashion
with general neurologists completing the tool before referral.10
Furthermore, the reference standard in our study was the con-
sensus decision of a single-center multidisciplinary DBS team.
No standardized guidelines exist for the selection of DBS candi-
dates for PD, and as a result, practices may vary between DBS
centers. Our team performs mostly STN DBS. Other centers
may routinely perform globus pallidus interna DBS in addition
to STN DBS and may apply different criteria for DBS candi-
dacy depending on the target. Our study also carries inherent
selection bias, in that it includes only patients who have already
been referred and does not address the issue of the many
patients who may be appropriate, but who were either not
offered or declined referral. Given these considerations, the
results of our study may not be generalizable.
Although our results will need to be validated at other DBS
centers utilizing non–movement disorder specialists in a pro-
spective fashion, we found that the Stimulus decision tool was a
better screening measure to assess DBS candidacy in PD patients
than the FLASQ-PD. The implementation of easy-to-use algo-
rithms such as the Stimulus scale could be an effective way to
improve access of care to DBS centers among patients with PD,
and future studies focused on these topics are warranted.
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